Advanced Enzyme Technologies (ADVENZYMES) Aandelenoverzicht
Advanced Enzyme Technologies Limited houdt zich samen met haar dochterondernemingen bezig met onderzoek, ontwikkeling, productie en marketing van enzymen en probiotica in India, Europa, de Verenigde Staten, Azië en internationaal. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 2/6 |
| Toekomstige groei | 2/6 |
| Prestaties in het verleden | 5/6 |
| Financiële gezondheid | 6/6 |
| Dividenden | 4/6 |
Beloningen
Risicoanalyse
Geen risico's gedetecteerd voor ADVENZYMES uit onze risicocontroles.
ADVENZYMES Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Advanced Enzyme Technologies Limited Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | ₹322.70 |
| 52 Week Hoogtepunt | ₹419.00 |
| 52 Week Laag | ₹251.95 |
| Bèta | 0.69 |
| 1 maand verandering | -12.08% |
| 3 maanden verandering | 14.68% |
| 1 Jaar Verandering | -4.46% |
| 3 jaar verandering | 13.73% |
| 5 jaar verandering | -20.17% |
| Verandering sinds IPO | 17.33% |
Recent nieuws en updates
If EPS Growth Is Important To You, Advanced Enzyme Technologies (NSE:ADVENZYMES) Presents An Opportunity
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
ADVENZYMES: Stable Case Balances Model Assumptions And Upcoming Dividend Decisions
Analysts have kept their ₹370 price target on Advanced Enzyme Technologies unchanged, citing slightly adjusted assumptions for discount rate, revenue growth, profit margin and future P/E that, in their view, broadly offset each other in the valuation model. Analyst Commentary Recent commentary on Advanced Enzyme Technologies highlights a mix of optimism about the company’s positioning and caution around execution and valuation assumptions, which feeds into how analysts are thinking about the ₹370 target.Recent updates
If EPS Growth Is Important To You, Advanced Enzyme Technologies (NSE:ADVENZYMES) Presents An Opportunity
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...ADVENZYMES: Stable Case Balances Model Assumptions And Upcoming Dividend Decisions
Analysts have kept their ₹370 price target on Advanced Enzyme Technologies unchanged, citing slightly adjusted assumptions for discount rate, revenue growth, profit margin and future P/E that, in their view, broadly offset each other in the valuation model. Analyst Commentary Recent commentary on Advanced Enzyme Technologies highlights a mix of optimism about the company’s positioning and caution around execution and valuation assumptions, which feeds into how analysts are thinking about the ₹370 target.ADVENZYMES: Steady Cash Assumptions And Upcoming Board Decisions Will Shape Returns
Narrative update on Advanced Enzyme Technologies The analyst price target for Advanced Enzyme Technologies is held steady at ₹370, as analysts point to only very small adjustments in assumptions for discount rate, revenue growth, profit margin and forward P/E after reviewing recent research on comparable companies. Analyst Commentary Recent Street research on other mid-cap service companies has given analysts a reference point as they revisit models for Advanced Enzyme Technologies, even though those reports focus on a different stock.ADVENZYMES: Stable Margins And Refined Assumptions Will Guide Future Returns
Analysts kept the fair value estimate for Advanced Enzyme Technologies steady at ₹370, citing modest adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions rather than any change in their core outlook. Analyst Commentary Analysts keeping fair value at ₹370 are focusing on how well Advanced Enzyme Technologies can execute on its current plan rather than changing their fundamental view of the stock.ADVENZYMES: Steady Risk And Margins Will Support Future Upside
Analysts have kept their fair value estimate for Advanced Enzyme Technologies steady at ₹370. They cited updated assumptions around the discount rate, growth, margins and future P/E that reflect fine tuning of their models rather than a change in overall conviction.ADVENZYMES: Steady Assumptions And Risk Profile Will Support Future Upside
Analysts have kept the fair value estimate for Advanced Enzyme Technologies steady at ₹370, with only small adjustments to the discount rate, growth, margin and future P/E assumptions informing this unchanged price target. Analyst Commentary Bullish Takeaways Bullish analysts see support for the ₹370 fair value estimate from the decision to keep key model assumptions, such as growth and margins, broadly consistent rather than revising them sharply.ADVENZYMES: Refined Risk Assumptions And Stable Outlook Will Support Upside
Analysts have maintained their fair value estimate for Advanced Enzyme Technologies at ₹370, making small changes to assumptions such as a slightly lower discount rate and marginally adjusted long-term growth and P/E inputs after revisiting their models. Analyst Commentary Bullish Takeaways Bullish analysts see the reaffirmed fair value of ₹370 as supported by refreshed assumptions, suggesting that the refined discount rate and long term inputs still back the existing valuation framework for Advanced Enzyme Technologies.ADVENZYMES: Free Cash Flow Momentum And Cleaner Portfolio Will Drive Upside
Analysts have maintained their fair value estimate for Advanced Enzyme Technologies at ₹370.0 per share, while slightly adjusting assumptions on discount rate, growth, margins and future P/E to reflect updated free cash flow trends and a cleaner portfolio. They expect these factors to support improvement in the second half.ADVENZYMES: Stable Assumptions And Future P/E Reset Will Drive Upside
Analysts have kept their price target for Advanced Enzyme Technologies steady at ₹370, citing largely unchanged assumptions around the discount rate, revenue growth, profit margin and future P/E in their updated models. What's in the News A board meeting is scheduled on January 31, 2026 to consider and approve unaudited financial results for the quarter and nine months ended December 31, 2025 (Key Developments).ADVENZYMES: Future P/E Reset Will Signal Upside Potential For Shares
Analysts have trimmed their fair value estimate for Advanced Enzyme Technologies from ₹440 to ₹370, citing updated assumptions around discount rates, revenue growth, profit margins, and a lower future P/E multiple. What's in the News Board meeting scheduled for January 31, 2026, to consider and approve the unaudited financial results for the quarter and nine months ended December 31, 2025 (Key Developments).Advanced Enzyme Technologies Limited's (NSE:ADVENZYMES) Share Price Not Quite Adding Up
There wouldn't be many who think Advanced Enzyme Technologies Limited's ( NSE:ADVENZYMES ) price-to-earnings (or "P/E...Preventive Health And Green Chemistry Will Expand Future Markets
Key Takeaways Expansion into health, wellness, and sustainable enzymatic solutions, along with new B2C initiatives, positions for growth and improved margins as consumer demand rises. International diversification, R&D investment, and increased capacity utilization support long-term product differentiation, earnings stability, and operating leverage.Here's What's Concerning About Advanced Enzyme Technologies' (NSE:ADVENZYMES) Returns On Capital
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Amongst other things...Advanced Enzyme Technologies' (NSE:ADVENZYMES) Dividend Will Be ₹1.20
The board of Advanced Enzyme Technologies Limited ( NSE:ADVENZYMES ) has announced that it will pay a dividend of ₹1.20...Advanced Enzyme Technologies (NSE:ADVENZYMES) Is Due To Pay A Dividend Of ₹1.20
The board of Advanced Enzyme Technologies Limited ( NSE:ADVENZYMES ) has announced that it will pay a dividend of ₹1.20...Is Advanced Enzyme Technologies (NSE:ADVENZYMES) A Risky Investment?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...After Leaping 26% Advanced Enzyme Technologies Limited (NSE:ADVENZYMES) Shares Are Not Flying Under The Radar
Advanced Enzyme Technologies Limited ( NSE:ADVENZYMES ) shareholders have had their patience rewarded with a 26% share...We Think Shareholders Are Less Likely To Approve A Pay Rise For Advanced Enzyme Technologies Limited's (NSE:ADVENZYMES) CEO For Now
Key Insights Advanced Enzyme Technologies' Annual General Meeting to take place on 25th of July Salary of ₹6.69m is...Advanced Enzyme Technologies (NSE:ADVENZYMES) Has Affirmed Its Dividend Of ₹1.00
The board of Advanced Enzyme Technologies Limited ( NSE:ADVENZYMES ) has announced that it will pay a dividend of ₹1.00...Advanced Enzyme Technologies' (NSE:ADVENZYMES) Returns On Capital Not Reflecting Well On The Business
What are the early trends we should look for to identify a stock that could multiply in value over the long term...Advanced Enzyme Technologies (NSE:ADVENZYMES) Will Want To Turn Around Its Return Trends
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Advanced Enzyme Technologies (NSE:ADVENZYMES) Could Be Struggling To Allocate Capital
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? In a perfect world...Advanced Enzyme Technologies (NSE:ADVENZYMES) Will Want To Turn Around Its Return Trends
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Amongst other things...Rendement voor aandeelhouders
| ADVENZYMES | IN Chemicals | IN Markt | |
|---|---|---|---|
| 7D | 0.5% | 1.9% | 1.0% |
| 1Y | -4.5% | -4.6% | -1.4% |
Rendement versus industrie: ADVENZYMES kwam overeen met de Indian Chemicals industrie, die het afgelopen jaar een rendement opleverde van -4.6 %.
Rendement versus markt: ADVENZYMES presteerde slechter dan Indian Market, dat het afgelopen jaar een rendement van -1.4 % opleverde.
Prijsvolatiliteit
| ADVENZYMES volatility | |
|---|---|
| ADVENZYMES Average Weekly Movement | 6.6% |
| Chemicals Industry Average Movement | 6.3% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in IN Market | 9.3% |
| 10% least volatile stocks in IN Market | 4.1% |
Stabiele aandelenkoers: ADVENZYMES heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de Indian markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 7% ) van ADVENZYMES is het afgelopen jaar stabiel geweest.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1957 | 338 | n/a | www.advancedenzymes.com |
Advanced Enzyme Technologies Limited houdt zich samen met haar dochterondernemingen bezig met onderzoek, ontwikkeling, productie en marketing van enzymen en probiotica in India, Europa, de Verenigde Staten, Azië en internationaal. Het bedrijf biedt voedingssupplementen op basis van enzymen en probiotica voor menselijke gezondheidszorg en diervoeding, groente- en fruitverwerking, bakken, brouwen en mouten, zetmeel- en graanverwerking, eiwitmodificatie, gistverwerking, zuivel- en kaasverwerking en olie- en vetverwerking, evenals voor speciale toepassingen, biobrandstoffen en biokatalyse. Het bedrijf levert non-food enzymen voor textiel-, leer-, pulp- en papierverwerking, evenals reinigings- en schoonmaakmiddelen.
Advanced Enzyme Technologies Limited Samenvatting
| ADVENZYMES fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | ₹35.56b |
| Inkomsten(TTM) | ₹1.69b |
| Inkomsten(TTM) | ₹7.46b |
Is ADVENZYMES overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| ADVENZYMES resultatenrekening (TTM) | |
|---|---|
| Inkomsten | ₹7.46b |
| Kosten van inkomsten | ₹1.93b |
| Brutowinst | ₹5.53b |
| Overige uitgaven | ₹3.84b |
| Inkomsten | ₹1.69b |
Laatst gerapporteerde inkomsten
Mar 31, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | 15.07 |
| Brutomarge | 74.13% |
| Nettowinstmarge | 22.62% |
| Schuld/Eigen Vermogen Verhouding | 1.2% |
Hoe presteerde ADVENZYMES op de lange termijn?
Bekijk historische prestaties en vergelijkingDividenden
Betaalt ADVENZYMES een betrouwbaar dividend?
Zie ADVENZYMES dividendgeschiedenis en benchmarks| Advanced Enzyme Technologies dividenddata | |
|---|---|
| Ex Dividend Datum | Jul 24 2026 |
| Betaaldatum dividend | Aug 30 2026 |
| Dagen tot Ex-dividend | 17 days |
| Dagen tot dividendbetaaldatum | 54 days |
Betaalt ADVENZYMES een betrouwbaar dividend?
Zie ADVENZYMES dividendgeschiedenis en benchmarksBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/07/06 12:41 |
| Aandelenkoers aan het einde van de dag | 2026/07/06 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2026/03/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Advanced Enzyme Technologies Limited wordt gevolgd door 4 analisten. 1 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Nandan Chakraborty | Axis Capital Limited |
| Abhishek Navalgund | Centrum Broking Limited |
| null null | DBS Bank Ltd |